Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan 1;81(1):15-17.
doi: 10.1097/FJC.0000000000001376.

Magnitude of Low-density Lipoprotein Reduction and Impact on Major Cardiovascular Outcomes

Salvatore Giordano  1 , Luigi Spadafora  2 , Giuseppe Biondi-Zoccai  3   4 , Marco Bernardi  2
Affiliations

Magnitude of Low-density Lipoprotein Reduction and Impact on Major Cardiovascular Outcomes

Salvatore Giordano et al. J Cardiovasc Pharmacol. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

G. Biondi-Zoccai has consulted for Cardionovum, CrannMedical, Innovheart, Meditrial, Microport, Opsens Medical, Replycare, Teleflex, and Terumo. The remaining authors report no conflicts of interest.

References

    1. Saglietto A, Manfredi R, Elia E, et al. Cardiovascular disease burden: Italian and global perspectives. Minerva Cardiol Angiol. 2021;69:231–240.
    1. Stamler J, Daviglus ML, Garside DB, et al. Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity. JAMA. 2000;284:311–318.
    1. Silverman MG, Ference BA, Im K, et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA. 2016;316:1289–1297.
    1. Cholesterol Treatment Trialists (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670–1681.
    1. Mach F, Baigent C, Catapano AL, et al.; ESC Scientific Document Group. ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111–188.

Substances